Almomani E, Lashhab R, Alexander RT, Cordat E. The carboxyl-terminally truncated kidney anion exchanger 1 R901X dRTA mutant is unstable at the plasma membrane. Am J Physiol Cell Physiol 310: C764 -C772, 2016. First published March 16, 2016 doi:10.1152/ajpcell.00305.2015.-Mutations in the SLC4A1 gene coding for kidney anion exchanger 1 (kAE1) cause distal renal tubular acidosis (dRTA). We investigated the fate of the most common truncated dominant dRTA mutant kAE1 R901X. In renal epithelial cells, we found that kAE1 R901X is less abundant than kAE1 wild-type (WT) at the plasma membrane. Although kAE1 WT and kAE1 R901X have similar half-lives, the decreased abundance of kAE1 R901X at the surface is due to an increased endocytosis rate and a decreased recycling rate of endocytosed proteins. We propose that, in polarized renal epithelial cells, the apically mistargeted kAE1 R901X mutant is endocytosed faster than kAE1 WT and its recycling to the basolateral membrane is delayed. This resets the equilibrium, such that kAE1 R901X resides predominantly in an endomembrane compartment, thereby likely participating in development of dRTA disease.
BICARBONATE IS THE PREDOMINANT extracellular buffer minimizing changes in plasma pH. Type A and B intercalated cells in the renal collecting duct participate directly in the maintenance of bicarbonate levels. In polarized type A intercalated cells, the concomitant activity of at least three proteins, cytosolic carbonic anhydrase II, apical H ϩ -ATPase, and the basolateral kidney anion exchanger 1 (kAE1) that is encoded by the SLC4A1 gene, ensures proper bicarbonate reabsorption back into the blood (9) . Other proteins, such as SLC26A7 or SLC26A11, may also play a role in this process (21, 25, 41) . When mutated, the gene encoding basolateral kAE1 induces dominant or recessive distal renal tubular acidosis (dRTA), a disease characterized by metabolic acidosis, hypokalemia, nephrocalcinosis, and failure to thrive in children (2) . kAE1 dRTA mutants are usually mistrafficked to the endoplasmic reticulum, the Golgi, or the apical membrane, instead of to the normal site of residence, the basolateral membrane (4, 26, 27, 35, 36) .
A growing number of point or frameshift mutations in SLC4A1 that cause dRTA affect the cytosolic COOH terminus of kAE1 (17, 20, 30, 42) . The integrity of the cytosolic COOH terminus plays a crucial role in normal kAE1 targeting to the cell surface, as truncation of the last five amino acids is enough to reduce cell surface abundance of kAE1 by 50% in human embryonic kidney (HEK-293) cells (11) . The COOH-terminally truncated kAE1 R901X mutant (numbering is based on erythroid AE1 protein) was first identified in patients with dRTA (20) . Patients carrying this dominant mutation develop the disease at an older age than those with recessive dRTA mutations and do not present hematological symptoms. Red blood cells from patients carrying this mutation show a reduced abundance of AE1 to ϳ60% of normal individuals (35) . In Madin-Darby canine kidney (MDCK), pig LLC-PK1, erythroleukemia K562, and HEK-293 cells, kAE1 WT is predominantly located at the plasma membrane (14, 34, 39) . In polarized MDCK and LLC-PK1 cells, the protein resides at the basolateral membrane (8, 14, 34) . In erythroleukemia K562 and HEK-293 cells, murine erythroid Ae1 (eAe1) is internalized in a clathrin-dependent pathway, but the eAe1 domain involved in the process is unknown (39) .
The COOH-terminal domain of kAE1 physically interacts with cytosolic carbonic anhydrase II, forming a functional metabolon that directly provides the exchanger with one of its substrates (37, 38) . The COOH terminus of kAE1 also interacts with glyceraldehyde-3 phosphate dehydrogenase (GAPDH) (33) and the ␤-subunit of the Na ϩ -K ϩ -ATPase pump in type A intercalated cells (32) . This interaction is important for kAE1 residency at the basolateral membrane. In addition, the COOHterminal domain encompasses the phosphorylatable tyrosine 904 (40) that is part of a canonical tyrosine-based YXX⌽ motif, ⌽ being a bulky, hydrophobic residue. Phosphorylation of the tyrosine 904 residue is important for kAE1 residency at the basolateral membrane in polarized MDCK cells (40) . Tyrosine 904 participates in the interaction of kAE1 with GAPDH in kidneys and MDCK cells (33) , as well as the interaction of kAE1 with adaptor proteins (1, 29) . kAE1 R901X is mistrafficked to the apical membrane in MDCK I cells or to apical and basolateral membranes in MDCK and LLC-PK1 cells (14, 34) . The engineered kAE1 Y904A/V907A double mutant localizes exclusively to the apical membrane of MDCK I cells (34) . Therefore, the integrity of the cytosolic COOH terminus of kAE1 appears to be important for the protein's localization.
The phosphorylation status of tyrosine 904 located within the cytosolic COOH terminus of kAE1 regulates the abundance of kAE1 at the plasma membrane, possibly by governing endocytosis and recycling of the protein (40) . We reasoned that the kAE1 R901X dRTA mutant lacks tyrosine 904, which could potentially affect kAE1 protein endocytosis and recycling. We therefore examined kAE1 WT and R901X abundance at the plasma membrane, stability, endocytosis, and recycling in a renal epithelial cell line.
MATERIALS AND METHODS
Plasmid constructs and antibodies. pcDNA3 plasmid constructs containing human kAE1 wild-type (WT) and R901X cDNA with a myc or hemagglutinin (HA) epitope in position 557 (in the 3rd extracellular loop) were used to express kAE1 protein in LLC-PK1 cells (26) . The mouse monoclonal antibody that detects the myc epitope was purchased from Cell Signaling Technology (Boston, MA). The mouse monoclonal antibody that detects the HA epitope was purchased from Covance (Princeton, NJ).
Cell culture. LLC-PK1 (catalog no. CL-101) and HEK-293T (catalog no. CRL-11268) cells were purchased from American Type Culture Collection (Manassas, VA). LLC-PK1 cells expressing kAE1 WT were transiently transfected using X-tremeGENE 9 (Roche Applied Science) or prepared according to methods previously described (8) . Briefly, HEK-293 cells were transfected with p-VPack-GP, p-VPack-VSV-G, and pFB-Neo-kAE1-myc (carrying a myc epitope in position 557) WT or mutant plasmids using X-tremeGENE 9. Cell culture supernatants containing infectious viral particles were added to dividing LLC-PK1 cells complemented with 8 g/ml Polybrene (Sigma-Aldrich, Oakville, ON, Canada). After 24 h of incubation, a heterogenous population of LLC-PK1 cells expressing kAE1 was selected with 3 mg/ml G418 (Geneticin, Sigma-Aldrich). The cells were further maintained in DMEM-F12 medium containing 10% FBS, 3 mg/ml Geneticin, and 1 mg/ml penicillin-streptomycin. For immunofluorescence experiments, 50% confluent LLC-PK1 cells were transfected with 1 g of cDNA and 4 l of X-tremeGENE 9.
Functional assay. Untransfected or kAE1-myc WT-or R901X-expressing 70% confluent LLC-PK1 cells were grown on 11 ϫ 7.5-mm glass coverslips and treated as previously described (5, 6, 31) . Briefly, the coverslips were rinsed three times with serum-free Opti-MEM (Gibco) before incubation with 10 M BCECF-AM (Sigma) for up to 1 h at 37°C. The coverslips were then placed in fluorescence cuvettes at room temperature, and the cells were perfused with Ringer buffer (5 mM glucose, 5 mM potassium gluconate, 1 mM calcium gluconate, 1 mM magnesium sulfate, 10 mM HEPES, 2.5 mM NaH2PO4, and 25 mM NaHCO3) containing 140 mM chloride. The perfusing solution was switched to a chloride-free medium containing 140 mM gluconate to induce intracellular alkalization. BCECF intracellular fluorescence was calibrated with buffers at pH 6.5, 7.5, or 7.0 containing 100 M nigericin sodium salt (Sigma). The Ringer buffers were continuously perfused with 19:1 air-CO2. A fluorometer (Photon Technologies International, London, ON, Canada) was used to read the fluorescence fluctuations generated by the samples. Excitation wavelengths at 440 and 490 nm and emission wavelength at 510 nm were used (calibrated to the fluorometer). Transport rates of the cells were determined by linear regression of the initial pH variation (first 60 s), normalized to pH calibration measurements. All measurements were done using Felix software.
Western blotting. Confluent LLC-PK1 cells expressing kAE1-myc WT or R901X mutant were lysed in PBS containing 1% Triton X-100 and protease inhibitors (1 g/ml aprotinin, 2 g/ml leupeptin, 1 g/ml pepstatin A, and 100 g/ml PMSF). Total protein concentration was measured using the bicinchoninic acid assay (Pierce, Rockford, IL). kAE1 proteins in the lysates were detected by immunoblotting with mouse anti-myc antibodies overnight at 4°C. The blots were further incubated with anti-mouse secondary antibody coupled to horseradish peroxidase for 1 h at room temperature. Enhanced chemiluminescence [ECL Western Blotting Substrate (Thermo Scientific) or ECL Prime Western Blotting Detection Reagent (GE Healthcare, Wauwatosa, WI)] was used to detect proteins. Relative band intensities were determined using the freeware ImageJ.
Cell surface biotinylation. Confluent LLC-PK1 cells expressing kAE1-HA WT or R901X were incubated twice with EZ-Link Sulfo-NHS-SS-Biotin reagent (1 mg/ml; Pierce) at 4°C for 15 min in borate buffer (10 mM boric acid, 145 mM NaCl, 7.2 mM KCl, and 1.8 mM CaCl2, pH 9). Excess biotin was quenched with 100 mM glycine in PBS four times for 1 min each. The cells were lysed in 300 l of TNT lysis buffer (50 mM Tris·HCl, 150 mM NaCl, 1% Triton X-100, 0.2% SDS, 1 g/ml aprotinin, 2 g/ml leupeptin, 1 g/ml pepstatin A, and 100 g/ml PMSF); 10% of the lysate was kept as total lysate, and the remaining 90% was incubated with 100 l of streptavidin-agarose resin (Thermo Scientific) for 1 h at 4°C. Cell surface proteins were eluted with 50 l of Laemmli buffer that contained 15% ␤-mercaptoethanol. Samples were immunoblotted with a mouse anti-HA antibody to detect kAE1 protein. Relative band intensities were determined using ImageJ. To quantify the ratios of surface kAE1, we considered that amounts loaded in the "total kAE1" fraction represented only one-ninth of the amount incubated with avidin beads.
Cycloheximide treatment. LLC-PK1 cells stably expressing kAE1-HA WT or R901X were treated with 10 g/ml cycloheximide (Fluka, Buchs, Switzerland) for 0, 4, 8, or 24 h and then lysed in PBS containing 1% Triton X-100 and protease inhibitors. Protein concentration was measured using the bicinchoninic acid assay. Samples were loaded on SDS-polyacrylamide gels, and mouse anti-HA antibody was used for immunoblotting to detect both kAE1 proteins. Relative band intensities were determined using ImageJ.
Endocytosis experiment. Semiconfluent LLC-PK1 cells were transfected with a total of 1 g of kAE1-myc WT or R901X cDNA using 4 l of X-tremeGENE 9 transfection reagent. After 24 h, the cells were incubated with mouse anti-myc antibody for 45 min on ice. The antibody was washed three times with cold PBS before incubation with warm DMEM-F12 medium at 37°C for 20 min to induce endocytosis. An acid wash was performed with a citrate buffer (40 mM citric acid, 100 mM KCl, and 135 mM NaCl, pH 1.5), which was added to the cells for 10 min on ice to wash out nonendocytosed antibodies. The cells were then fixed with 4% paraformaldehyde for 10 min on ice, permeabilized with 0.2% Triton X-100 for 15 min, and blocked with 1% BSA for 20 min before incubation with anti-mouse Alexa 488 antibody (Invitrogen) to detect endocytosed kAE1-myc. Mouse anti-myc antibody was added again for 20 min followed by anti-mouse DyLight 649 antibody to detect nonendocytosed kAE1. 4=,6-Diamidino-2-phenylindole (DAPI) was used to stain the nucleus.
To inhibit endocytosis with dynasore, semiconfluent LLC-PK1 cells stably expressing kAE1-myc were incubated at 37°C in DMEM-F12 medium without FBS for 1 h to induce serum starvation and promote uptake of transferrin (Tfn)-Alexa 488 conjugate (Life Technology, Carlsbad, CA). The cells were incubated with mouse anti-myc antibody for 45 min on ice prior to three washes with cold PBS and then with dynasore hydrate (120 M; catalog no. D7G93, Sigma) and Tfn-Alexa 488 conjugate (10 g/ml; ThermoFisher Scientific) in DMEM-F12 medium without FBS for 20 min at 37°C to induce endocytosis. After three washes, citrate buffer was added for 10 min on ice to wash out the nonendocytosed antibodies. The endocytosis experiment proceeded as described above. Colocalization between kAE1-myc and Tfn-Alexa 488 was measured using Pearson's correlation coefficient with Fiji freeware. High-resolution images were acquired using the ϫ60 oil-immersion objective of an Angstrom illumination system (Quorum Technologies) equipped with an OptiGrid structured illumination (Qioptiq), excitation and emission filter wheels (Ludl Electronic Products), and a Flash 4.0 camera (Hamamatsu). The Angstrom illumination system and associated hardware were mounted to the 100% sideport of a fully motorized inverted microscope (model DMI6000, Leica Microsystems). All hardware was controlled with Metamorph software (Molecular Devices). For quantification of endocytosed kAE1 protein, fluorescence intensities were measured from Ն50 cells from 3 independent experiments using the Volocity imaging analysis program (Perkin Elmer, Waltham, MA). The histograms for endocytosed kAE1 show the ratio of endocytosed kAE1 to total kAE1 for each cell from three independent experiments.
Caveolin colocalization with kAE1. Semiconfluent LLC-PK1 cells were transfected with kAE1-myc and pcDNA3 as control or with kAE1-myc and caveolin 1-Venus using FuGENE 6 transfection re-agent (Roche) as described for the 12-well plate (0.5 g of cDNA and 3 l of FuGENE 6 reagent). At 24 h after transfection, the cells were incubated with mouse anti-myc antibody diluted in DMEM-F12 medium for 45 min on ice. After three washes with cold PBS, the cells were incubated with warm DMEM-F12 medium at 37°C for 20 min to induce endocytosis as described above. Anti-mouse Cy3 antibody was used to detect endocytosed kAE1 (green in Fig. 3 ). Total kAE1 was detected by mouse anti-myc antibody followed by anti-mouse antibody coupled to DyLight 649 for 20 min. DAPI was added to detect the nuclei. Caveolin 1-Venus is shown in red in Fig. 3 . Colocalization of kAE1-myc with caveolin was measured using Pearson's correlation coefficient with Fiji analysis software.
Recycling experiment. Semiconfluent LLC-PK1 cells were transfected with kAE1-myc WT or R901X cDNA. After 24 h, the cells were incubated with mouse anti-myc antibody for 45 min on ice and then washed three times with cold PBS. Warm DMEM-F12 medium was added, and the cells were incubated at 37°C for 20 min to induce endocytosis. After an acid wash with citrate buffer at pH 1.5 on ice to remove nonendocytosed antibodies, the cells were incubated again with warm DMEM-F12 medium for 80 min at 37°C to induce protein recycling and then fixed at 4°C with 4% paraformaldehyde. The cells were blocked with 1% BSA and incubated with goat anti-mouse secondary antibody coupled to Alexa 488 to detect recycled proteins. The cells were permeabilized, blocked again, and incubated with mouse anti-myc antibody and then with anti-mouse DyLight 649 secondary antibody to detect total kAE1. DAPI was used to stain the nuclei. Samples were examined using an Olympus IX81 microscope equipped with a Nipkow spinning disk optimized by Quorum Technologies (Guelph, ON, Canada) and a ϫ60 oil-immersion objective. For quantification of recycled kAE1 protein, the fluorescence intensities were measured from Ն25 cells from 3 independent experiments using the Volocity imaging analysis program. The histograms for recycled kAE1 show the ratio of recycled kAE1 to total kAE1 for each cell from three independent experiments.
Statistical analysis. All experiments were independently repeated at least three times. Results are expressed as means Ϯ SE. All statistical comparisons were made using unpaired Student's t-test. P Ͻ 0.05 was considered significant.
RESULTS AND DISCUSSION
In nonpolarized LLC-PK1 cells, kAE1 WT is more abundant than the kAE1 R901X mutant at the plasma membrane. To understand the physiological role of the kAE1 cytosolic COOH-terminal domain in the protein's trafficking, we compared the relative amount of cell surface kAE1 WT with kAE1 R901X mutant. We used renal epithelial LLC-PK1 cells, because when expressed in these cells, kAE1 is targeted to the basolateral membrane (14) , indicating that processing of kAE1 is similar to that in renal intercalated cells. Additionally, kAE1 WT is as active in LLC-PK1 as in MDCK cells (6) . Indeed, in LLC-PK1 cells transiently expressing kAE1, we measured initial transport rates of 0.24 Ϯ 0.03 and 0.22 Ϯ 0.02 (SE) pH unit/min for kAE1 WT (n ϭ 5) and kAE1 R901X mutant (n ϭ 6), respectively (data not shown). In contrast, cells transfected with an empty vector displayed an initial transport rate of 0.03 Ϯ 0.01 pH unit/min (n ϭ 3). Furthermore, in transiently transfected MDCK and LLC-PK1 cells, the kAE1 R901X mutant was found at the apical and basolateral membranes (14, 34) . These cells are also easier to transfect than other renal epithelial cell types such as MDCK cells. We used immunofluorescence microscopy to determine the relative amount of cell surface kAE1 WT and R901X mutant. The kAE1 WT and R901X constructs carry an extracellular HA or myc epitope in the third extracellular loop to facilitate protein detection (10) . Because we were unable to obtain polarized LLC-PK1 cells expressing sufficient amounts of kAE1 WT or mutant protein, we performed the cell surface biotinylations and immunofluorescence experiments on nonpolarized LLC-PK1 cells. To detect surface kAE1 by immunofluorescence, fixed, but nonpermeabilized, LLC-PK1 cells transiently expressing kAE1 WT myc or kAE1 R901X myc were incubated with an anti-myc antibody (green in Fig. 1A ). After permeabilization, intracellular kAE1 was detected by incubation of the cells with the same primary antibody followed by a different secondary antibody (blue). The green fluorescence intensity represents the amount of cell surface kAE1 and was normalized to the blue fluorescence intensity (total kAE1). By calculating these ratios on Ն50 cells from 3 independent experiments, we found significantly less kAE1 R901X mutant than kAE1 WT at the cell surface, as the ratio of cell surface kAE1 R901X mutant was 0.37 Ϯ 0.06 (SE, n ϭ 3), which is 60% less than that of kAE1 WT (0.94 Ϯ 0.11, n ϭ 3) at the steady state (Fig. 1B) . A similar trend was observed by cell surface biotinylation (Fig. 1, C and D) , with the ratio of surface R901X significantly reduced to 0.15 Ϯ 0.01 (n ϭ 3) compared with 0.19 Ϯ 0.01 (n ϭ 3) for kAE1 WT. These results confirm that the kAE1 R901X mutant is less abundant than kAE1 WT at the plasma membrane.
Our results support the hypothesis that the last 11 amino acids of the kAE1 protein are indeed required to maintain the protein at the plasma membrane, as the R901X mutant was found to be less abundant at the cell surface. We next asked whether the decreased amount of cell surface protein was accompanied by a destabilization of the mutant protein in LLC-PK1 cells.
Half-life of the kAE1 R901X truncated mutant is similar to that of kAE1 WT. The kAE1 R901X mutant may be recognized as misfolded by the quality-control machinery in the cells and may be prematurely degraded, which would result in decreased abundance at the plasma membrane. We next determined whether the kAE1 R901X mutant is as stable as kAE1 WT in renal epithelial cells. LLC-PK1 cells expressing kAE1 WT or kAE1 R901X were incubated with the protein synthesis inhibitor cycloheximide for up to 24 h, and the relative amount of kAE1 remaining in the samples was determined by immunoblotting (Fig. 2) . We observed half-lives of ϳ15 h for kAE1 WT and R901X. Similar results were obtained in MDCK cells (24) , supporting the notion that kAE1 R901X is not prematurely degraded in renal epithelial cells. Therefore, the decrease in plasma membrane abundance of kAE1 R901X is not due to its instability and premature degradation.
Premature degradation has been observed in endocytosed proteins that are recognized as "misfolded" by the peripheral quality-control machinery (3, 5) . However, we observed that the overall stability of the kAE1 R901X mutant was not different from that of kAE1 WT (Fig. 2) . This result suggests that the kAE1 R901X mutant is likely not recognized as misfolded by the peripheral quality-control machinery. The http://ajpcell.physiology.org/ decrease in plasma membrane abundance of kAE1 R901X could originate from a decreased processing of newly synthesized kAE1, an increased internalization rate of kAE1 R901X, or slow recycling of kAE1 R901X back to the cell surface. The amount of immature kAE1 R901X relative to kAE1 WT (Figs. 1C and 2A) is consistent with the mutant not being processed as efficiently as kAE1 WT to the plasma membrane. Nevertheless, endocytosis and recycling of kAE1 R901X may also be affected. We thus hypothesized that COOH-terminal truncation impairs the protein's endocytosis and recycling rates. We first wondered whether the reduced amount of kAE1 R901X originates from an increased rate of endocytosis. However, as the endocytosis pathway that human kAE1 uses is not described in the literature, we first determined whether the human kAE1 protein is endocytosed in a clathrin-dependent or -independent pathway (7, 15) .
kAE1 is endocytosed via a clathrin-dependent pathway. We used immunofluorescence microscopy to characterize the kAE1 endocytosis pathway by developing a protocol that allows detection of endocytosed kAE1, but not kAE1 protein remaining on the cell surface. Intact LLC-PK1 cells expressing kAE1 WT or kAE1 R901X were incubated with primary antibody prior to an acid wash to remove the antibody attached to cell surface kAE1 proteins. The appropriate secondary antibody was then added to the intact cells. As seen in Fig. 3A (top), no primary antibody remained at the cell surface after the Total kAE1 Fig. 1 . In nonpolarized LLC-PK1 cells, kidney anion exchanger 1 (kAE1) wild-type (WT) is more abundant than the kAE1 R901X mutant at the plasma membrane. A: immunofluorescence of LLC-PK1 cells stained for cell surface and total kAE1. LLC-PK1 cells expressing kAE1 were grown on glass coverslips. After fixation, they were incubated with mouse anti-myc antibody to detect surface kAE1 and then with a secondary antibody coupled to Alexa 488 (green). Cells were permeabilized, and total kAE1 was detected with an anti-myc antibody followed by a secondary antibody coupled to DyLight 649 (blue). Scale bar ϭ 10 m. B: ratio of green fluorescence intensity (surface kAE1) to blue fluorescence intensity (total kAE1) in LLC-PK1 cells transfected with kAE1. Fluorescence intensities were measured using the Volocity imaging analysis program. Values are means Ϯ SE for Ն50 cells for each condition from 3 independent experiments. *P Ͻ 0.05 vs. kAE1 WT. C: cell surface biotinylation. Confluent LLC-PK1 cells stably expressing kAE1-hemagglutinin (HA) WT or R901X were incubated with membrane-impermeable EZ-Link Sulfo-NHS-SS-Biotin reagent, lysed, and incubated with streptavidin resin. Surface proteins were eluted from the beads with Laemmli reagent and immunoblotted with mouse anti-HA antibody to detect kAE1. OE, Complex glycosylated kAE1 proteins; , core-glycosylated kAE1 proteins. D: ratio of surface kAE1 to total kAE1 in cells transfected with kAE1 WT or R901X mutant, as measured by cell surface biotinylation. Band intensities were determined by densitometric analysis (using ImageJ freeware), taking into account that "total kAE1" fractions correspond to 1/9th of the kAE1 amount used in "surface kAE1" fractions. Values are means Ϯ SE for Ͼ3 independent experiments. *P Ͻ 0.05 vs. kAE1 WT.
acid wash, as evidenced by the absence of green staining after the acid wash. In contrast, cells that were acid-washed after endocytosis showed internalized kAE1 proteins (green in Fig.  3A, bottom) . Therefore, the acid wash efficiently removed all antibodies remaining on the cell surface. Once the protocol was established, we characterized the kAE1 endocytosis pathway. We first asked whether endocytosed kAE1 colocalizes with endocytosed Tfn receptor, which is known to be internalized via a clathrin-dependent pathway (18) . As a control, we used dynasore, an inhibitor of dynamindependent endocytosis that blocks Tfn endocytosis (22) . Cell surface kAE1-myc proteins were first labeled with anti-myc antibody in serum-starved LLC-PK1 cells, and endocytosis was initiated in the presence of dynasore or vehicle and Tfn-Alexa Fluor 488 conjugate (red in Fig. 3B ). Cells were then acid-washed to remove antibodies remaining at the cell surface, fixed, and permeabilized, and endocytosed kAE1 proteins were detected (green). Total kAE1 expression was detected by readdition of the anti-myc antibody (blue). Representative images (Fig. 3B, compare columns 1 and 2) show that dynasore inhibited endocytosis of kAE1 and Tfn, as neither green (kAE1) nor red (Tfn) was observed after the acid wash. In the absence of dynasore (Fig. 3B, column 1) , kAE1 and Tfn colocalized in a perinuclear compartment, likely in recycling endosomes (18) . Measurements of colocalization of kAE1 with Tfn gave a Pearson's correlation coefficient of 0.36, showing that kAE1 and Tfn colocalize to some extent (Fig. 3C ).
To confirm these findings, we determined whether endocytosed kAE1 colocalizes with endocytosed caveolin protein, which is endocytosed in a clathrin-independent pathway (23, 28) . LLC-PK1 cells expressing kAE1-myc and caveolin-yellow fluorescent protein were incubated with mouse anti-myc antibody (red) to detect endocytosed kAE1 (Fig. 3B, column  3) . Colocalization measurement showed that endocytosed kAE1 did not colocalize with caveolin protein (Pearson's correlation coefficient ϭ Ϫ0.12; Fig. 3C ). Overall, these experiments infer that kAE1 is endocytosed via a clathrin-dependent pathway and that endocytosed kAE1 colocalizes with the Tfn receptor, a protein known to accumulate in recycling endosomes after clathrin-mediated endocytosis (12) . In agreement with our findings, in erythroleukemia K562 and HEK-293 cells, murine eAe1 is also endocytosed in a clathrindependent pathway and colocalizes with the Tfn receptor after 20 min (39). We next determined whether kAE1 WT is endocytosed at the same rate as the COOH-terminally truncated kAE1 R901X mutant.
COOH-terminal kAE1 mutant R901X is endocytosed faster than kAE1 WT. To compare endocytosis rates of kAE1 WT and R901X mutant, the cells were incubated with anti-myc antibody at 4°C for 45 min. After several washes, the cells were transferred to 37°C for 20 min (the shortest time to detect endocytosed kAE1). After removal of the antibody remaining at the cell surface by acid wash, the cells were fixed and permeabilized, and endocytosed proteins were detected (green in Fig. 4A ). Intracellular kAE1 protein was subsequently detected using the same primary antibody and a different secondary antibody (blue). Comparison of endocytosed kAE1 WT and R901X using the Volocity imaging analysis program showed that the ratio of kAE1 R901X internalized after 20 min of incubation at 37°C was significantly higher than that of kAE1 WT [0.19 Ϯ 0.01 vs. 0.14 Ϯ 0.01 (SE) from Ն50 cells from 3 independent experiments] in nonpolarized LLC-PK1 cells (Fig. 4B) . The increased amount of endocytosed kAE1 R901X compared with kAE1 WT could explain the lower abundance of kAE1 R901X than kAE1 WT at the steady state.
The kAE1 R901X mutant is truncated at the last 11 amino acids, a fragment that contains three important motifs: 1) the Y 904 DEV canonical interaction motif with adaptor proteins, 2) the D 902 EYDE motif, which interacts with GAPDH, and 3) the putative PDZ1-binding domain A 908 MPV, which may be responsible for kAE1 apical mistargeting in polarized cells (13, 17, 34) . The instability and the rapid endocytosis of kAE1 R901X may be due to the absence of one or several of the above-described motifs. Consistent with this, we observed that the absence of the last 11 amino acids of kAE1 influences the endocytosis rate of kAE1 protein. Overall, our experiments show that truncation of the last 11 amino acids increases the kAE1 endocytosis rate. We next determined whether kAE1 R901X recycles back to the cell surface at the same rate as kAE1 WT.
The COOH-terminal kAE1 R901X mutant recycles less efficiently than kAE1 WT to the plasma membrane. To determine whether kAE1 R901X is less abundant at the plasma membrane because it is less efficiently recycled back to the plasma membrane of LLC-PK1 cells, cell surface kAE1 WT and R901X proteins were labeled with anti-myc antibody before protein endocytosis was allowed to proceed. After the acid wash, endocytosed kAE1 proteins were allowed to recycle back to the plasma membrane by reincubation of the cells at 37°C. The washed cells were fixed, and recycled proteins were detected (green). Cells were next permeabilized, and total kAE1 protein was detected by reincubation with anti-myc antibody (blue in Fig. 5A ). Cells expressing kAE1 WT and R901X stained green, indicating recycling of kAE1 to the cell surface. In contrast to kAE1 WT, green staining for kAE1 R901X displayed bright and well-defined particles of unknown nature (Fig. 5A) . By normalizing green fluorescence intensities corresponding to recycled kAE1 WT or R901X to blue fluorescence intensity corresponding to total kAE1, we determined the ratio of recycled kAE1 proteins after 80 min. As seen in Although the kAE1 R901X mutant is less abundant at the plasma membrane, we did not observe its premature degradation in LLC-PK1 cells. However, the mutant was endocytosed faster and recycled less efficiently to the plasma membrane than kAE1 WT protein. Previously, the kAE1 G701D mutant was found to be prematurely endocytosed and degraded due to the recognition of the mutant as misfolded by the peripheral quality-control machinery (5). We therefore hypothesize that the difference between kAE1 R901X and G701D originates from a cellular mechanism that is different from that degrading the misfolded G701D mutant. The kAE1 R901X mutant has been studied in various cell lines such as MDCK, MDCK I, LLC-PK1, and inner medullary collecting duct (IMCD) cells (14, 34) . Interestingly, the mutant kAE1 localized differently depending on the cell line in which it was expressed. In MDCK I cells, the kAE1 R901X mutant localized exclusively to the apical membrane, while in MDCK, LLC-PK1, and IMCD cells, it trafficked in a nonpolarized way to apical and basolateral membranes. These differences likely reflect the different trafficking machineries in the various cell types. The R901X mutation truncates the last 11 amino acids of the protein. These last 11 amino acids encompass various binding sites, including a binding site for GAPDH (33) , a potential PDZ-binding site (17) , and a binding site for the mu1A subunit of the adaptor protein complex 1A (1, 19) . All these interactions are important for normal trafficking and stability of the kAE1 protein. Although usually considered a better model for proximal tubule than collecting duct cells, LLC-PK1 cells traffic kAE1 to the basolateral membrane (14, 34) , as seen in type A intercalated cells. In LLC-PK1, IMCD, and MDCK cells, kAE1 R901X was mistrafficked to the apical and basolateral membranes (14, 34) . Finally, these cells are easier to transfect than other renal epithelial cell lines such as MDCK cells, which made possible completion of the experiments described above. Therefore, studies in this cell line are likely as relevant as studies in MDCK cells.
The presence of the mutant at the apical membrane is likely the main reason for development of dRTA. However, the acid-base status of the cells affects kAE1 WT endocytosis and recycling back to the plasma membrane in renal epithelial cells (40) . Thus our finding that the mutant recycles less efficiently than the kAE1 WT protein provides additional valuable insights into the pathophysiology associated with this mutant in renal epithelial cells. kAE1 protein forms dimers in epithelial cells, and dominant dRTA mutants such as kAE1 R901X retain kAE1 WT intracellularly in heterodimers (10) . Therefore, it is possible that the defective recycling of the kAE1 R901X mutant also affects kAE1 WT recycling. Experiments clarifying whether kAE1 R901X is located at the basolateral membrane in intercalated cells are essential, because the mutant may impair kAE1 WT/kAE1 R901X heterodimer recycling and decrease the bicarbonate reabsorption capacity of the cells in dRTA patients. Overall, this decreased abundance at the plasma membrane and altered recycling provide a possible physiological mechanism aggravating the development of distal renal tubular acidosis in patients carrying this mutation.
